Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

RedHill Biopharma

Request full access

RedHill (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on proprietary drugs for gastrointestinal diseases

Raleigh, United StatesFounded 2009Biotech & Life Sciences

About RedHill Biopharma

RedHill Biopharma is a specialty biopharmaceutical company headquartered in Raleigh, NC, with a strong focus on gastrointestinal (GI) diseases. The company operates primarily in the U.S. market, where it has built a dedicated sales force specializing in GI treatments. RedHill's commercial portfolio includes prescription drugs such as omeprazole, amoxicillin, rifabutin, naloxegol, and rifamycin. These medications are used to treat various GI conditions, making RedHill a key player in this niche market.

RedHill's business model revolves around both the commercialization of existing GI products and the development of new treatments. The company generates revenue by selling its prescription drugs to healthcare providers and pharmacies. Additionally, RedHill is actively involved in drug development, with a pipeline that includes treatments for COVID-19, among other conditions. The company recently received approval for a Phase 2/3 COVID-19 study in Russia, highlighting its commitment to addressing urgent healthcare needs.

RedHill also engages in strategic activities to protect its interests and ensure market integrity. For instance, the company has sought SEC review of suspicious trading activity, demonstrating its vigilance in maintaining a fair trading environment.

In summary, RedHill Biopharma serves healthcare providers and patients in the U.S. GI market through a combination of commercialized products and ongoing drug development. The company makes money by selling its prescription drugs and advancing new treatments through clinical trials.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2013

RedHill Biopharma in the Raleigh ecosystem

Live from Dealroom

The RedHill Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • US Biomedical Advanced Research and Development Authority

Series A3 investors entered at this stage

  • Fidelity Ventures
  • Shmuel Kabili
  • Lautman Foundation

Series B and later5 investors entered at this stage

  • Nomura
  • ROTH Capital Partners
  • OrbiMed
  • Migdal Insurance and Financial Holdings
  • Yelin Lapidot Investment House
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See RedHill Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.